Literature DB >> 31181992

Toxic Peripheral Neuropathies: Agents and Mechanisms.

William M Valentine1.   

Abstract

Toxic peripheral neuropathies are an important form of acquired polyneuropathy produced by a variety of xenobiotics and different exposure scenarios. Delineating the mechanisms of neurotoxicants and determining the degenerative biological pathways triggered by peripheral neurotoxicants will facilitate the development of sensitive and specific biochemical-based methods for identifying neurotoxicants, designing therapeutic interventions, and developing structure-activity relationships for predicting potential neurotoxicants. This review presents an overview of the general concepts of toxic peripheral neuropathies with the goal of providing insight into why certain agents target the peripheral nervous system and produce their associated lesions. Experimental data and the main hypotheses for the mechanisms of selected agents that produce neuronopathies, axonopathies, or myelinopathies including covalent or noncovalent modifications, compromised energy or protein biosynthesis, and oxidative injury and disruption of ionic gradients across membranes are presented. The relevance of signaling between the main components of peripheral nerve, that is, glia, neuronal perikaryon, and axon, as a target for neurotoxicants and the contribution of active programmed degenerative pathways to the lesions observed in toxic peripheral neuropathies is also discussed.

Entities:  

Keywords:  Schwann cell; axon degeneration; axonopathy; demyelination; myelinopathy; neuronopathy; toxic neuropathy

Mesh:

Substances:

Year:  2019        PMID: 31181992      PMCID: PMC6901819          DOI: 10.1177/0192623319854326

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  245 in total

1.  A case of severe neurotoxicity associated with exposure to 1-bromopropane, an alternative to ozone-depleting or global-warming solvents.

Authors:  Makoto Samukawa; Gaku Ichihara; Nobuyuki Oka; Susumu Kusunoki
Journal:  Arch Intern Med       Date:  2012-09-10

Review 2.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

Authors:  Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon
Journal:  Pain       Date:  2014-09-23       Impact factor: 6.961

3.  Effects of triethyltin on different ATPases, 5'-nucleotidase and phosphodiesterases in grey and white matter of rabbit brain and their relation with brain edema.

Authors:  J S Wassenaar; A M Kroon
Journal:  Eur Neurol       Date:  1973       Impact factor: 1.710

4.  1,2-diacetylbenzene, the neurotoxic metabolite of a chromogenic aromatic solvent, induces proximal axonopathy.

Authors:  M S Kim; M I Sabri; V H Miller; R J Kayton; D A Dixon; P S Spencer
Journal:  Toxicol Appl Pharmacol       Date:  2001-12-01       Impact factor: 4.219

5.  An immunohistochemical study of phospholipase A2 in peripheral nerve during Wallerian degeneration.

Authors:  J A Paul; N A Gregson
Journal:  J Neuroimmunol       Date:  1992-07       Impact factor: 3.478

Review 6.  Mechanisms of distal axonal degeneration in peripheral neuropathies.

Authors:  Christopher R Cashman; Ahmet Höke
Journal:  Neurosci Lett       Date:  2015-01-21       Impact factor: 3.046

7.  Tellurium blocks cholesterol synthesis by inhibiting squalene metabolism: preferential vulnerability to this metabolic block leads to peripheral nervous system demyelination.

Authors:  M Wagner-Recio; A D Toews; P Morell
Journal:  J Neurochem       Date:  1991-12       Impact factor: 5.372

Review 8.  Wallerian demyelination: chronicle of a cellular cataclysm.

Authors:  Nicolas Tricaud; Hwan Tae Park
Journal:  Cell Mol Life Sci       Date:  2017-06-09       Impact factor: 9.261

Review 9.  Diagnosing and managing diabetic somatic and autonomic neuropathy.

Authors:  Shazli Azmi; Maryam Ferdousi; Alise Kalteniece; Hamad Al-Muhannadi; Abdulrahman Al-Mohamedi; Nebras H Hadid; Salah Mahmoud; Harun A Bhat; Hoda Y A Gad; Adnan Khan; Georgios Ponirakis; Ioannis N Petropoulos; Uazman Alam; Rayaz A Malik
Journal:  Ther Adv Endocrinol Metab       Date:  2019-02-04       Impact factor: 3.565

Review 10.  Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity.

Authors:  Alessia Chiorazzi; Sara Semperboni; Paola Marmiroli
Journal:  Toxics       Date:  2015-08-07
View more
  3 in total

1.  Characterization in Dual Activation by Oxaliplatin, a Platinum-Based Chemotherapeutic Agent of Hyperpolarization-Activated Cation and Electroporation-Induced Currents.

Authors:  Wei-Ting Chang; Zi-Han Gao; Shih-Wei Li; Ping-Yen Liu; Yi-Ching Lo; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

2.  Myelination, axonal loss and Schwann cell characteristics in axonal polyneuropathy compared to controls.

Authors:  Eva Placheta-Györi; Lea Maria Brandstetter; Jakob Zemann-Schälss; Sonja Wolf; Christine Radtke
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

Review 3.  Models and methods to study Schwann cells.

Authors:  Samuele Negro; Marco Pirazzini; Michela Rigoni
Journal:  J Anat       Date:  2022-01-05       Impact factor: 2.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.